Xenetic Biosciences Inc
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, pancreatic ductal adenocarcinoma, colorectal carcinoma, a… Read more
Xenetic Biosciences Inc (XBIO) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.166x
Based on the latest financial reports, Xenetic Biosciences Inc (XBIO) has a cash flow conversion efficiency ratio of -0.166x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-658.25K) by net assets ($3.96 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Xenetic Biosciences Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Xenetic Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Xenetic Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Xenetic Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Connected Minerals Ltd
AU:CML
|
-0.119x |
|
NYESA VALOS CO.EO 001
F:7NY0
|
N/A |
|
Wilhelmina
OTCQX:WHLM
|
0.004x |
|
QPR Software Oyj
HE:QPR1V
|
-0.282x |
|
ARCONTECH GROUP LS-125
F:KTSA
|
N/A |
|
STS Group AG
XETRA:SF3
|
0.115x |
|
Emdeki Utama Tbk PT
JK:MDKI
|
0.013x |
|
KD Corporation
KQ:044180
|
-0.058x |
Annual Cash Flow Conversion Efficiency for Xenetic Biosciences Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Xenetic Biosciences Inc from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $6.01 Million | $-2.82 Million | -0.469x | -11.67% |
| 2023-12-31 | $9.80 Million | $-4.11 Million | -0.420x | -23.35% |
| 2022-12-31 | $13.65 Million | $-4.65 Million | -0.340x | -32.19% |
| 2021-12-31 | $18.39 Million | $-4.74 Million | -0.258x | +26.26% |
| 2020-12-31 | $12.22 Million | $-4.27 Million | -0.349x | +6.04% |
| 2019-12-31 | $17.21 Million | $-6.40 Million | -0.372x | +42.99% |
| 2018-12-31 | $9.91 Million | $-6.46 Million | -0.652x | -724.13% |
| 2017-12-31 | $14.30 Million | $1.49 Million | 0.104x | +119.23% |
| 2016-12-31 | $16.17 Million | $-8.79 Million | -0.543x | +32.25% |
| 2015-12-31 | $6.61 Million | $-5.30 Million | -0.802x | +31.82% |
| 2014-12-31 | $10.48 Million | $-12.33 Million | -1.176x | -145.26% |
| 2013-12-31 | $12.62 Million | $-6.05 Million | -0.480x | -59.16% |
| 2012-12-31 | $20.78 Million | $-6.26 Million | -0.301x | -- |